NCT05930613View on ClinicalTrials.gov

Certolizumab in Recurrent Implantation Failure (RIF)

PHASE3RecruitingINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2029

Conditions
Recurrent Unexplained Implantation Failure
Interventions
DRUG

Certolizumab (CIMZIA® ; TNF-α antagonist)

400mg of certolizumab injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.

DRUG

Placebo (NaCl 0.9 % solution)

NaCl 0,9% injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.

Trial Locations (1)

75012

RECRUITING

Saint-Antoine Hospital - APHP, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER